
Merck (MRK) Stock Forecast & Price Target
Merck (MRK) Analyst Ratings
Bulls say
Merck & Co is projected to experience strong growth in the latter half of 2025 and into 2026 and 2027, supported by a robust portfolio that includes the Capvaxive pneumococcal vaccine and RSV antibody, which are anticipated to help the company capture significant market share. The optimistic outlook for Keytruda's subcutaneous formulation, coupled with expected revenues from new products like clesrovimab for RSV and islatravir for HIV treatment, positions Merck advantageously, even as it prepares for the loss of exclusivity on certain products. Additionally, ongoing positive trial results for Winrevair and MK-8527 could further enhance Merck’s revenue streams and overall market presence, solidifying its positive financial trajectory.
Bears say
Merck & Co. is facing a fundamentally negative outlook primarily due to anticipated significant declines in Keytruda sales as a result of biosimilar competition and Medicare negotiations, with projections indicating a potential decrease of up to 58% post-loss of exclusivity. Additionally, the company's financial performance is being impacted by underwhelming sales figures from its other products, such as Winrevair, which fell short of consensus estimates and is modeled to experience a considerable reduction in US sales by 2030. The overall decrease in business development activity and the challenges in effectively transitioning Keytruda to subcutaneous formulations further exacerbate concerns regarding revenue sustainability and market positioning.
This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.
Merck (MRK) Analyst Forecast & Price Prediction
Start investing in Merck (MRK)
Order type
Buy in
Order amount
Est. shares
0 shares